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Abstract for the Master’s Paper 
Introduction: Low Dose Computed Tomographic (LDCT) scanning for lung cancer screening 
recently received a Grade B recommendation from the United States Preventive Services Task 
Force (USPSTF). Many uncertainties regarding potential harms of this relatively new cancer 
screening modality exist. In this paper I explore the psychological implications of lung cancer 
screening and report findings from a study on patient perceptions of potential benefits and harms 
of lung cancer screening, along with perceptions of lung cancer risk. 
Methods: I conducted a systematic review of the recent literature to show current evidence of 
psychological harms of lung cancer screening. I used this review to guide my research and 
discussion of results from a survey conducted among general medicine clinic patients who were 
at increased risk for lung cancer, due to long-term smoking history. This study surveyed 
participants on their understanding of potential benefits and risks of LDCT screening, as well as 
their thoughts about the screening process in general and their personal risk profile. 
Results: After reviewing 1088 abstracts, 12 studies met inclusion criteria. The studies found that 
all participants have relatively high cancer risk perceptions and that people with abnormal screen 
results experienced increased distress. The studies had mixed results regarding changes in 
distress for the screening groups as a whole (regardless of their screening outcome). Overall, 
distress for all participants seems to return to baseline over time. My survey study found that 
individuals who are eligible for screening overestimate the mortality benefits of screening, 
underestimate the harms of false positives and additional diagnostic and invasive procedures, and 
overestimate their personal risk of being diagnosed with and dying from lung cancer. When 
asked why people should get screened for lung cancer, participants most frequently report early 
detection and early treatment leading to better health outcomes. 
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Conclusion: Abnormal lung cancer screening findings and surveillance of pulmonary nodules 
are distressing for patients. However, we lack adequate, high-quality, generalizable evidence to 
make conclusions about the screening experience for all participants, regardless of screening 
outcome. Eligible screening patients who were part of my survey study were not familiar with 
the screening process and were overly-optimistic about the precision and effectiveness of LDCT 
screening. Patients may make more informed choices if they are aware of the potential harms and 
their personal risk of suffering from lung cancer. 
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Preface 
 
 It is common knowledge today that smoking is directly linked to lung cancer and 
cardiovascular disease, some of the most common causes of death in the U.S. The first claims 
that tobacco smoke was a risk factor for lung cancer came in 1912, with much skepticism 
following until the 1950's and 60's.
1
 Evidence for increasing incidence of male lung cancer in the 
1930's was based on official mortality statistics and pathology reports from autopsies among 
pulmonary specialist physicians.
1
 Plausible etiologies were debated including tobacco, domestic 
fire smoke, road tars used in construction, and possibly even late sequelae from infectious 
diseases such as influenza or tuberculosis.
1
 In a 1953 experiment researchers painted tobacco 
tar on the skin of mice and demonstrated growth of tumors on the animals.
2
  Large tobacco 
companies were quick to respond to these claims and tobacco sales continued to rise until 
peaking in 1982.
2
 Much of the later decline in domestic sales may be attributed to the efforts of 
the U.S. Surgeon General's office, which has made tobacco use a pre-eminent concern over the 
last 4 decades. In 1962 the Surgeon General enlisted a committee of experts which reviewed over 
7,000 articles and in January of 1964 the Surgeon General issued a report highlighting the 
negative effects of tobacco, ultimately concluding that smoking was responsible for a 70 percent 
increase in mortality and a nine to ten-fold increase in lung cancer risk compared to non-
smokers.
3
  
 Fifty years later smoking still contributes to worldwide morbidity and mortality. 
Currently smoking is associated with 440,000 premature deaths and $193 billion of health care 
costs annually in the U.S.; about 46 million American adults (~20% of the population) continue 
to smoke.
4
 There is marked disparity among education levels: 41.3% usage for those with GED 
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compared to 5.7% usage among those with a graduate degree; and among income level: 31.5% 
usage for those below vs. 19.6% usage for those at or above the poverty level.
4
 Locally, smoking 
in NC has a higher prevalence than the national average: 20.3% vs. 17.9% in one survey from 
2011.
5
  
 Technology is ever-advancing, attempting to improve health by detecting cancer earlier 
in hopes to improve the treatment of disease. 
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Psychological Harms of Lung Cancer Screening: A Systematic Review 
 
Abstract 
 
Background: Lung cancer screening with LDCT has recently been recommended for 
individuals ages 55 to 80 with a 30 pack-year smoking history based on a positive balance of 
benefits and harms. However, there is significant potential for screening to have psychological 
effects on patients. In this review, I assess the available literature regarding the psychological 
effects of screening and indeterminate pulmonary findings. 
Methods: Using standardized methods, I performed a systematic review of the literature to 
synthesize available evidence regarding the psychological effects of lung cancer screening on 
patients at increased risk of lung cancer. I searched Medline, CINAHL, and PsycINFO databases 
from 2002-2014 for cohort, cross-sectional, randomized control, and qualitative studies for 
various psychological harms associated with screening. I followed this search with standardized 
data abstraction and quality rating processes for eligible studies. I then developed an overall, 
qualitative synthesis of study results and conclusions. 
Results: I included twelve studies in the review, organizing them into three categories: 1) 
screening in asbestos-exposed Europeans, 2) surveillance of pulmonary nodules, 3) screening in 
large cancer screening trials. The European asbestos studies found mixed results regarding 
anxiety scores in the samples as a whole but were concordant in that individuals with abnormal 
results suffered from increased anxiety. The pulmonary nodule studies found increased anxiety 
and confusion regarding the finding and surveillance of pulmonary nodules. The cancer 
screening trial studies found varying results for the study groups as a whole, but the highest 
quality studies found increased anxiety in those with abnormal screening results, and that all 
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participant groups had relatively high cancer risk perceptions. Most study participants were in 
relatively good physical and mental health at baseline. One study suggested that the common 
practice of measuring psychological status just prior to screening may not represent an accurate 
baseline in participants, due to anxiety surrounding the screening process. 
Conclusion: The common practice of measuring psychological variables immediately prior to 
screening may give a false impression of participants’ baseline condition, given the anxiety 
around the time of screening. Good quality and generalizable evidence regarding psychological 
effects of participating in lung cancer screening is lacking, but there is general agreement that 
abnormal lung cancer screening findings and surveillance of pulmonary nodules is distressing for 
patients. This is a clinically important conclusion given the high likelihood of abnormal 
screening results that necessitate further management in individuals eligible for lung cancer 
screening. 
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Introduction 
 
 In July, 2013 the USPSTF published a systematic review on lung cancer screening; the 
conclusions based on the past decades of various trials gave heavy weight to a recent, large, 
American trial of “good-quality:” the National Lung Screening Trial (NLST).6 The NLST 
enrolled 53,554 people at increased risk for lung cancer based on smoking history and found that 
screening with LDCT vs. chest x-ray resulted in a 20% reduction in lung cancer mortality, and a 
6.7% reduction in all-cause mortality.
7
 Later in 2013 the USPSTF updated its recommendation 
for lung cancer screening from an I-statement (insufficient evidence), to a grade B-
recommendation concluding that for those at increased risk of lung cancer, there is “moderate 
certainty… of moderate net benefit” of LDCT screening.8  
 The NLST reported that through three rounds of screening over 2 years, 39.1% of those 
in the LDCT group received at least one abnormal screening results; 96.4% of these were false-
positive results that involved additional diagnostic and invasive testing for confirmation.
7
 
Because of the high false positive rate in individuals with long-term smoking history, lung 
cancer screening has been controversial regarding the balance of benefit from reduced mortality 
with possible harms.
9
 Possible physical harms include invasive procedures required to reach 
definitive diagnosis, and radiation exposure. Overdiagnosis is also highly probable, represented 
by the reported excess lung cancers diagnosed in the LDCT arm of the NLST. Financial and 
opportunity costs of time spent and medical resource utilization should also be weighed against 
potential benefits. Another important factor in overall well-being of patients in screening 
programs is their psychological wellbeing; this aspect has not been examined to the same degree 
as physical harms of screening.
6
 The goal of this review is to investigate the literature regarding 
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psychological effects of lung cancer screening with special attention to surveillance of 
indeterminate findings, and anxiety and knowledge regarding lung cancer specific risk. This 
review also serves to guide and inform my personal research regarding risk perceptions among 
those eligible for screening as they balance perceived benefits and harms of their potential 
experience with lung cancer screening. 
 
Methods: 
 Key Questions: 
1. What are the psychological harms associated with lung cancer screening? 
2. What are the psychological effects of indeterminate pulmonary findings such as lung 
nodules and other abnormalities that require further testing or surveillance? 
 
Eligibility Criteria 
  I used a PICOTTS table (Populations, Interventions, Comparisons, Outcomes, Timing, 
Settings, and Study designs) to frame the questions answered in this review (Table 1). Given that 
widespread implementation LDCT screening was only recently recommended, these criteria 
were purposefully broad to maximize sensitivity of the search. The population of interest was 
individuals at increased risk for lung cancer undergoing lung cancer screening (by any modality), 
or surveillance of an indeterminate lung finding, excluding individuals with an existing lung 
cancer diagnosis. The intervention studied is the screening or surveillance process and any 
subsequent diagnoses that may result from participation in screening. I allowed multiple 
comparator groups including: individuals declining screening, individuals at baseline prior to 
participating in screening, the various arms of a screening trial, or general population norms. I 
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considered a wide array of outcomes to measure psychological effects such as cognitive and 
behavioral components of quality of life, general anxiety or distress measures, problems with 
sleep, fear, discomfort, stigma, health care adherence or utilization, and psychiatric diagnoses.  
 To focus on current screening modalities and relevant demographics, the time frame of 
the search was Jan 1, 2002 to Dec 31, 2013; roughly the last ten years. The year 2002 was also 
chosen because the research group in collaboration with this search had already begun searching 
literature from this date. I focused only on studies from Organisation for Economic Co-operation 
and Development countries to improve generalizability of samples, study techniques, and 
publication methods. The study types included were prospective and retrospective cohort, 
randomized controlled trials, case-control, and cross-sectional studies, and both quantitative and 
qualitative studies were considered to collect data from various possible sources. I believed that 
cross-sectional studies could be an important source of information, and few randomized studies 
would have been performed with valid outcome measures of interest. The search was limited to 
peer-reviewed, English-language studies that were published and searchable in the databases 
used for this review. 
  
Search Strategy 
  On Feb 17, 2014 we performed a systematic search of the databases PUBMED, 
CINAHL, and PsycInfo using the search strings found in Appendix B.  
  
Study Selection 
  After identifying articles by the search strategy, I screened studies by title and abstract 
excluding findings that were irrelevant to the key questions of the search. At this stage, I was 
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blinded to study authors, but used article title, journal name, and abstract to determine relevance. 
Various types of articles including reviews, editorials, and other commentaries were included at 
this stage to search references for any articles missed by the database search string. I hand-
searched reviews for additional relevant references. Though dual review of articles would be 
ideal, I reviewed abstracts and full text of all articles alone given that the goal of this review was 
to inform an area important to the research presented later in this paper, rather than an ultimate 
goal of publishing this review as a stand-alone article. 
 Articles selected for full text review included the following study designs: prospective 
and retrospective cohort, cross-sectional (quantitative and qualitative), and randomized 
controlled trials. 
  
Data Collection Processes 
 I collected information from the selected articles regarding psychological harms of lung 
cancer screening into a standardized data form to abstract relevant information from each article 
selected. This included the following information: study population characteristics and 
recruitment methods, study setting and design, interventions, comparator groups, instruments 
used to measure outcomes, measurement intervals, and overall study results.  
 The studies included use many different measurement tools. The Psychological 
Consequences Questionnaire (PCQ) was first used in breast cancer screening and was slightly 
modified in the Paris study for use in lung cancer screening.
10,11
 The Impact of Events Scale-
Lung Cancer (IES) is a modified scale used to measure distress through sub-scales of intrusion 
and avoidance of stressful events.
12
 The Medical Outcomes Study Short Form 12 (SF-12) 
measures general health related quality of life and contains a psychological component.
13
 The 
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Euroqol-5D (EQ-5D) is a measure of health related quality of life which includes measures of 
anxiety and depression.
14
 The State-Trait Anxiety Inventory (STAI-6) contains six items related 
to anxiety (calm, tense, upset, relax, content, worried) to determine relative anxiety levels.
15
 The 
Consequences of Screening in Lung Cancer (COS) questionnaire was originally developed for 
breast cancer screening; it measures anxiety, sleep, behavior, dejection, stigma, and guilt, among 
other psychosocial elements.
16
  These instruments have been validated and studies of validation 
techniques are referenced here for each instrument. Some studies developed customized 
measurement instruments of distress and risk perception; these studies referenced external 
validation sources of their instruments when necessary. 
  
Risk of bias in individual studies 
  I assessed articles for quality and strength of evidence using a grading scheme similar to 
that of the USPSTF. I recorded overall magnitude of effect measured in each study and judged 
each article by the overall certainty of effect (based the underlying study design and execution). I 
rated internal and external validity as good, fair, or poor using the USPSTF critical appraisal 
procedure manual.
17
 Internal validity ratings were based on relative degree of selection, 
measurement, and confounding biases and are a marker of how well the study answers the 
question set forth by that particular study.
18
 External validity ratings were based on how well the 
study’s results could be applied to answer this reviews key questions and are framed by the 
limitations inherent within each study.
19
 These guidelines are available in Appendix D. 
 
Synthesis  
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 I assessed the strength of evidence for all studies included using USPSTF procedure 
manual guidelines which consider six key questions to critical appraisal. This involves rating the 
body of evidence based on included studies’ appropriate design, quality, generalizability, number 
of studies and participant number within each study, and consistency of results across studies, 
among other factors.
20
 By considering the available evidence I judged a conceptual confidence 
interval to generate a strength of evidence rating based on criteria in Appendix D, Table a. 
 
Results: 
Study Selection: 
 The study selection process is outlined in the figure provided from the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (Appendix C). I identified twelve 
studies to inform the key questions of this review. The search strategy discovered a total of 1088 
unique articles that were screened by title and abstract. Hand searching references from reviews 
yielded one additional unique study for inclusion in full text review. I performed a full text 
review of 21 articles (including 4 reviews); to confirm studies reported relevant outcomes for the 
population of interest. Nine studies were excluded after full-text review including four reviews, 
two duplicate studies published in different journals, two studies with inappropriate outcomes, 
and one study with inappropriate comparison groups. 
 
Study Characteristics: 
 The studies included were grouped into 3 categories based on their sample populations. 
The first category involves lung cancer screening in European populations of asbestos-exposed 
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workers and includes two studies, both of which were prospective cohort samples. Outcomes in 
these studies were relative health-anxiety.  
 In the second category, three studies examined pulmonary nodules; two were qualitative 
cross-sectional interview studies that examined anxiety regarding indeterminate findings, one 
was a prospective cohort in a Cleveland Clinic lung cancer screening trial that focused on quality 
of life ratings and health care utilization. 
 The last and largest category contains seven studies that involve samples from large 
established screening trials. One study was a retrospective cohort sample from the Prostate, 
Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. The rest were prospective 
cohorts: three studies used samples from the Dutch-NELSON trial; two of these studies were the 
same sample but measured different outcomes. One study used a sample from the Danish Lung 
Cancer Screening Trial (DLCST), one evaluated participants of the Pittsburgh Lung Screening 
Trial, and one evaluated participants of the American NLST. The outcomes in these studies 
involved lung cancer distress, health-related quality of life, anxiety, medical adherence, and risk 
perception. 
 
Summary Measures 
 Category 1 studies involved lung cancer screening in European, asbestos-exposed 
workers. Vierikko’s study in Finland found anxiety decreased in all participants one year after 
high-resolution lung CT compared to baseline.
21
 The French asbestos sample showed increased 
abnormal PCQ scores (associated with greater distress) in individuals six months after screening 
compared to baseline (32.6% vs. 20.5% with abnormal score); additional analysis showed greater 
distress in those with abnormal findings, particularly pleural plaque and pulmonary nodules.
10
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 Category 2 studies involving pulmonary nodules examined the psychological burden of 
imaging surveillance and the uncertainty involved in receiving a diagnosis of a non-cancerous, 
indeterminate lung finding. In the Cleveland Clinic Screening Study, patients notified of 
pulmonary nodules had lower EQ-5D scores as well as increased imaging use at six-month 
follow up compared to those with normal screen results.
22
 The two qualitative studies involved 
interviews with patients about their experience of being diagnosed with a pulmonary nodule. 
Most patients initially assumes nodules were cancerous, almost all experienced at least mild 
distress upon diagnosis, some experienced distress lasting months, and many experienced 
frustration with physicians not fully addressing their concerns.
23,24
 Though mild distress is not 
defined, Slatore categorizes patient responses regarding worry and intrusive thoughts that do not 
impair daily activities as “mild”.23 
 Category 3 studies mostly involved psychological questionnaires in samples of 
participants in large screening trials. NLST participants in the screen arm did not have 
statistically significant changes in risk perception from baseline screen to 1-year follow up as a 
whole, or when stratified by smoking status or screen result; changes in smoking status at follow 
up were not associated with changes in risk perception. 
25
 DLCST participants in both control 
and screening arms (only those with negative screen results) had worse COS scores; there was no 
difference in mean increase of scores between screen and control arms.
26
  
 Among NELSON trial participants, one study measured baseline health-related quality of 
life using the SF-12, EQ-5D, STAI-6, and a lung-cancer-specific distress scale. Compared to 
baseline (prior to randomization, on average 165 days before screening) all participants had 
worse scores just prior to screening. Shortly after screening, lung-cancer specific distress scores 
were clinically elevated in those with indeterminate results.
27
 Two studies using the same sample 
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of NELSON participants examined different outcomes. One reported levels of discomfort 
experienced by lung cancer screening patients (50.5% of respondents report dreading the 
screening results), as well as health-related quality of life: no metrics (SF-12, EQ-5D, STAI-6, 
IES) had clinically relevant changes over time.
28
 The second study showed participants with 
higher risk perceptions prior to screening had higher distress and mental SF-12 component 
scores 6-months after screening; overall, fewer participants perceived their risk as high at follow 
up compared to 1-day before screening (10.5% vs. 14.6%).
29
  
 Participants in the Pittsburgh Lung Screening Trial had high baseline cancer risk 
perceptions that decrease after receiving a negative screen result. Those with non-negative screen 
results had increased STAI-6 and “fear of cancer” scores; anxiety increases were greater among 
current smokers, those with lower education, and those unmarried.
30
 There was one retrospective 
study in this category; it examined screening adherence rates in those with false positive vs. 
negative lung cancer screening results among participants in the PLCO trial. Participants with a 
false positive result had over 50% greater non-adherence and sub-group analysis showed 
increased non-adherence among African Americans (OR = 1.5), women (OR = 1.4), current 
smokers vs. never smokers (OR = 1.4), and older participants.
31
 
 These results, and other individual study characteristics, are summarized in Appendix E. 
 
Quality: 
 Category 1: The European-asbestos studies were rated poor regarding external validity 
because of the special population of asbestos-exposed workers, the use of nationalized health 
systems in France and Finland, and use of High-Resolution CT, whereas American lung cancer 
 19 
 
screening protocols employ LDCT. One study received a poor rating for internal validity due to 
the high proportion of symptomatic participants, as well as relatively low retention of 
participants with false positive screening results (positive results were excluded). 
 Category 2: Both qualitative studies were rated as good for internal validity based on well 
documented and appropriate study design, data collection and analysis, and overall clarity of the 
study (criteria in Appendix D). One of the qualitative studies was rated poor regarding external 
validity; this study was performed in a Veteran’s Affairs hospital, the sample has unique 
distinctions compared to the general population at increased risk for lung cancer. The Mazzone 
study had an external validity rating of poor because of the use of chest-x-ray as the screening 
mode, and because the sample had higher EQ-5D results than the general population matched for 
age; I would expect those eligible for lung cancer screening to have notably reduced quality of 
life scores, given extensive smoking history and associated comorbidities. 
 Category 3: The 2010 study by van den Bergh received a fair internal validity rating due 
to low response rates for all 4 measurement times, but was notable for its use of multiple well-
documented measurement instruments, four different measurement points with low loss-to-
follow up, and detailed statistical analysis section. The Bunge and Byrne studies were the only 
prospective, non-qualitative study that received good ratings for internal validity. The 2008 van 
den Bergh study was given a poor external validity rating due to the NELSON trial involving a 
European screening population (though many studies received a fair rating for this purpose). 
Additionally, the baseline sample health related quality of life scores were noted to be the same 
as that of the general population. As mentioned above, I would expect those eligible for lung 
cancer screening to have notably reduced quality of life scores. NELSON trial eligibility criteria 
require roughly half the smoking history as the NLST: around 15 pack-years, so these 
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participants are likely not as heavy smokers as people that might participate in American lung 
cancer screening programs. 
 I gave most articles fair ratings for internal validity based on minor flaws in research 
design, attrition and differential loss to follow up, variations in baseline groups, or other flaws in 
the criteria outlined in Appendix D. 
 Participation bias likely explains the relatively high mental and physical health appearing 
among participants of lung screening trials; additionally these participants were overwhelmingly 
white, with high levels of education. These trials were conducted in major academic centers with 
highly specialized clinicians and advanced technology, and results may not be relevant to 
application among the general U.S. population, therefore none of these articles received better 
than a fair rating for external validity. 
 Quality grades for each study are shown in Appendix E. 
  
Risk of bias across studies 
   This search was limited to English language articles and so studies that were published 
in other languages, or have yet to be translated into English, were not included. Other biases 
result from only searching through published literature that is accessible through the databases 
used in this search. Publication bias and language bias are inherent flaws of the search strategy 
that would be difficult to overcome given the limited resources of my search strategy.  
 
Strength of Evidence 
 The certainty of evidence for key question #1 (what are the psychological harms of 
screening?) is low given the limited number of good quality studies and the inconsistency of 
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some outcomes between studies. The certainty of evidence for key question #2 (what are the 
psychological effects of indeterminate pulmonary findings?) is moderate and approaching high, 
but is limited by the number of high quality studies. The generalizability of the results is a major 
limiting factor and the short time frame of the studies means that we cannot observe important 
long-term psychological effects.  
 
Conclusion 
 Overall there is mixed evidence regarding psychological effects of lung cancer screening. 
Category 1 studies had mixed results among populations of asbestos-exposed workers; though 
both showed increased anxiety in individuals with abnormal screening results, only the larger, 
higher quality French study showed higher psychological distress among all those screened, 
regardless of result. The Category 2 studies conclude that the finding of a pulmonary nodule is 
distressing and imaging use increases after such finding. The category 3 studies are also variable 
in conclusions. Though all showed increased anxiety in individuals with abnormal screening 
results (by measurements on EQ-5D, IES, and STAI-6, scores) this anxiety often reduced to 
baseline over time. When looking at the screening group as a whole, participants of the NLST 
and NELSON trials had no significant psychological changes over time (6 months to 1 year after 
screening). However, NELSON trial individuals with high risk perception at baseline have 
higher distress and, though overall risk perceptions decrease over time, they remain higher than 
actual risk. In one NELSON trial study, compared to pre-randomization (about half a year before 
screening), all those screened have worse psychological scores shortly before screening. These 
scores improve over time, except for those with indeterminate results. Finally, the PLCO trial 
showed increased health care non-adherence in those with false positive screen result. 
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 The limitations of the literature involve an inadequate number and quality of studies, 
particularly a lack of good-quality, prospective studies. Internal validity was limited by follow-
up in many studies, suggesting that patients in lung cancer screening may have poor adherence to 
the screening regimen. Additionally, the comparisons in some studies may be misleading. The 
use of various different measurement tools introduces heterogeneity into the findings of this 
review. Comparisons between test groups may also be misleading. Lung cancer is one of the 
most distressing of commonly screened cancer types.
32
 I questioned whether screened 
individuals would suffer greater anxiety from the screening process due to high rates of 
indeterminate and false-positive results. However, one might expect increased anxiety in 
volunteers that sign up for a screening intervention, which they might perceive as helpful in 
preventing mortality from lung cancer, who are assigned to the control arm that does not receive 
potentially beneficial screening. One study in particular showed better baseline psychological 
metrics when participants were measured prior to randomization (about six months prior to 
screening), suggesting that the measurement of psychological status shortly prior to the screening 
exam may not represent a true baseline measure for those undergoing screening. This is likely 
due to the anxiety surrounding the test and anticipation of receiving results. Most studies used 
samples from pre-existing lung screening trials which are inherently limited in external validity, 
due to participation bias of those being screened (evident by high quality of life, and skewed 
demographics), and expertise of investigators, clinicians, and equipment involved in evaluating 
and managing patients.  
 This review shows evidence that people receiving abnormal screening results experience 
increased anxiety. Some of the studies in this review show evidence for increased anxiety and 
distress in individuals who have high risk perceptions. Good quality, consistent evidence for 
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clinically significant psychological effects for the screening group as a whole is lacking in the 
current literature. Future research efforts should focus on developing well-designed, prospective, 
studies that measure long term psychological outcomes to inform patients and providers of this 
important type of harm inherent in lung cancer screening.  
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Tables and Figures 
Appendix A. PICOTSS Criteria: used to outline search strategy 
 Inclusion Exclusion 
Population Subjects at increased risk for lung 
cancer. OECD countries. 
Confirmed cancer diagnosis 
Intervention Lung cancer screening or surveillance of 
indeterminate lung findings 
Symptomatic diagnostic 
testing 
Comparison Single cohorts over time, different 
screening trial arms, screening trial 
results, population norms 
 
Outcomes Psychological harms including 
depression, anxiety, quality of life, risk 
perception, suicide 
Proxy outcomes 
Time of search Jan 1, 2002 – Dec 31, 2013  
Time for outcomes 
to appear 
Any None 
Settings Organization for Economic Co-operation 
and Development (OECD) countries 
Non-OECD countries 
Study Types RCT, pro/retrospective cohort, cross-
sectional, qualitative. Full text available. 
Non-peer reviewed. Non-
English language.  
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 Appendix B. Search Strategy 
PubMed: Feb 17, 2014. Found 987 
(Lung cancer*[tw] OR Lung Neoplasms[Mesh] OR lung nodule*[tw] OR pulmonary 
nodule*[tw]) AND (screening*[tw] OR early diagnosis[tw] OR early detection[tw] 
OR biops*[tw] OR surveillance[tw] OR watchful waiting[tw] OR overdiagnos*[tw] 
OR over diagnos*[tw] OR overdetect*[tw] OR over detect*[tw] OR 
insignifican*[tw]) AND (depress*[tw] OR distress[tw] OR stress*[tw] OR worry[tw] 
OR fear*[tw] OR anxiet*[tw] OR quality of life[tw] OR mental health[tw] OR mental 
disorders[tw] OR psycholog*[tw] OR psychosocial[tw] OR wellbeing[tw] OR well-
being[tw] OR emotion*[tw] OR false positive*[tw] OR stigma[tw] OR shame[tw] 
OR label*[tw] OR suicid*[tw]) 
Limits: Publication Dates From 2002/01/01 to 2013/12/31 
  
CINAHL via EBSCO: Feb 17, 2014. Found 178 
(MH "Lung Neoplasm*" OR “Lung cancer*” OR “lung nodule*” OR “pulmonary 
nodule*”) AND (screening* OR “early diagnosis” OR “early detection” OR biops* 
OR surveillance OR “watchful waiting” OR overdiagnos* OR “over diagnos*” OR 
overdetect* OR “over detect*” OR insignifican*) AND (depress* OR distress OR 
stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental health” OR 
“mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* 
OR “false positive*” OR stigma OR shame OR label* OR suicid*) 
Limits: Publication Date from 2002/01/01-2013/12/31 
  
PsycINFO via EBSCO: Feb 17, 2014. Found 68  
 ("Lung Neoplasm*" OR “Lung cancer*” OR “lung nodule*” OR “pulmonary 
nodule*”) AND (screening* OR “early diagnosis” OR “early detection” OR biops* 
OR surveillance OR “watchful waiting” OR overdiagnos* OR “over diagnos*” OR 
overdetect* OR “over detect*” OR insignifican*) AND (depress* OR distress OR 
stress* OR worry OR fear* OR anxiet* OR “quality of life” OR “mental health” OR 
“mental disorders” OR psycholog* OR psychosocial OR “well being” OR emotion* 
OR “false positive*” OR stigma OR shame OR label* OR suicid*) 
Limits: Publication Date from 2002/01/01-2013/12/31 
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Appendix C. Figure 1: Study Selection
33
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Appendix D: U.S. Preventive Services Task Force (USPSTF) Procedure Manual:  
Criteria for Assessing Internal Validity of Individual Studies
18
  
Randomized Controlled Trials and Cohort Studies 
Criteria: 
 Initial assembly of comparable groups: 
o For RCTs: adequate randomization, including first concealment and whether 
potential confounders were distributed equally among groups. 
o For cohort studies: consideration of potential confounders with either restriction or 
measurement for adjustment in the analysis; consideration of inception cohorts. 
 Maintenance of comparable groups (includes attrition, cross-overs, adherence, 
contamination). 
 Important differential loss to follow-up or overall high loss to follow-up. 
 Measurements: equal, reliable, and valid (includes masking of outcome assessment). 
 Clear definition of interventions. 
 All important outcomes considered. 
 Analysis: adjustment for potential confounders for cohort studies, or intention to treat 
analysis for RCTs. 
 
Definition of ratings based on above criteria: 
 Good: Meets all criteria: Comparable groups are assembled initially and maintained 
throughout the study (follow-up at least 80 percent); reliable and valid measurement 
instruments are used and applied equally to the groups; interventions are spelled out 
clearly; all important outcomes are considered; and appropriate attention to confounders 
in analysis. In addition, for RCTs, intention to treat analysis is used. 
 Fair: Studies will be graded "fair" if any or all of the following problems occur, without 
the fatal flaws noted in the "poor" category below: Generally comparable groups are 
assembled initially but some question remains whether some (although not major) 
differences occurred with follow-up; measurement instruments are acceptable (although 
not the best) and generally applied equally; some but not all important outcomes are 
considered; and some but not all potential confounders are accounted for. Intention to 
treat analysis is done for RCTs. 
 Poor: Studies will be graded "poor" if any of the following fatal flaws exists: Groups 
assembled initially are not close to being comparable or maintained throughout the study; 
unreliable or invalid measurement instruments are used or not applied at all equally 
among groups (including not masking outcome assessment); and key confounders are 
given little or no attention. For RCTs, intention to treat analysis is lacking. 
 
Criteria for Assessing External Validity (Generalizability) of Individual Studies
19
  
Study Population: The degree to which the people who were involved as subjects in the study 
constitute a special population because they were selected from a larger eligible population or 
were for other reasons unrepresentative of people who are likely to seek or be candidates for the 
preventive service. The selection has the potential to affect the following: 
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 Absolute risk: The background rate of outcomes in the study could be greater or less than 
what might be expected in asymptomatic people because of the inclusion/exclusion 
criteria, because of non-participation, or for other reasons. 
 Harms: The harms observed in the study could be greater or less than what might be 
expected in asymptomatic people. 
The following are features of the study population and the study design that may cause 
experience in the study to be different from what would be observed in the US primary care 
population: 
 Demographics (age, gender, ethnicity, education, income): The criteria for 
inclusion/exclusion or non-participation do not encompass the range of people likely to 
be candidates for the preventive services in the US primary care population. 
 Co-morbidities: the frequency of co-morbid conditions in the study population does not 
represent of the frequency likely to be encountered in people who seek the preventive 
service in the U.S. primary care population. 
 Special inclusion/exclusion criteria: There are other special inclusion/exclusion criteria 
that make the study population unrepresentative. 
 Refusal rate (ratio of included to not-included but eligible participants): The refusal rate 
among eligible study subjects is high, making the enrollees in the study unrepresentative 
even of the people eligible for the study. 
 Adherence (run-in phase, frequent contact to monitor adherence): The design of the study 
has features that may make the effect of the intervention in the study greater than it would 
be in a clinically observed population. 
 Stage in natural history of disease; severity of disease: the selection of subjects for the 
study includes people with at a stage that is earlier or later than would be found in people 
who are candidates for the preventive service. 
 Source, intensity of recruitment: The sources for recruiting subjects for the study and/or 
the effort and intensity of recruitment may distort the characteristics of the study subjects 
in ways that could increase the effect of the intervention as it is observed in the study. 
Situation: 
The degree to which the clinical experience in the situation in which the study was conducted is 
likely to be reproduced in other settings 
 Healthcare system: The clinical experience in the system in which the study was 
conducted is not likely to be the same as experience in other systems because, for 
example, the system provides essential services for free when these services are only 
available at a high cost in other systems. 
 Country: The clinical experience in the country in which the study was conducted is not 
likely to be the same as in the U.S. because, for example, services available in the U.S. 
are not widely available in the other country of study conduct or vice versa. 
 Selection of participating centers: The clinical experience in which the study was 
conducted is not likely to be same as in offices/hospitals/settings in which the service will 
be delivered to the U.S. primary care population because, for example, the centers have 
ancillary services not available generally. 
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 Time, effort, and system cost for the intervention: The time, effort, and cost to develop 
the service in the study is more than would be available outside the study setting. 
Providers: 
The degree to which the providers in the study have the skills and expertise likely to be available 
in general settings 
 Training to implement the intervention: The intervention in the study was done after 
giving providers special training not likely to be available or required in U.S. primary 
care settings. 
 Expertise, skill to implement intervention: The providers included in the study had 
expertise and/or skills at a level that is higher than the level likely to be encountered in 
typical settings. 
 Ancillary providers: The study intervention relied on ancillary providers who are not 
likely to be available in typical settings. 
Global Rating of External Validity (Generalizability): 
External validity is rated "good" if: 
 The study differs minimally from the US primary care population/situation/providers and 
only in ways that are unlikely to affect the outcome; it is highly probable (>90%) that the 
clinical experience with the intervention observed in the study will be attained in the US 
primary care setting. 
External validity is rated "fair" if: 
 The study differs from the US primary care population/situation/providers in a few ways 
that have the potential to affect the outcome in a clinically important way; it is only 
moderately probable (50%-89%) that the clinical experience with the intervention in the 
study will be attained in the US primary care setting. 
External validity is rated "poor" if: 
 The study differs from the US primary care population/ situation/ providers in many way 
that have a high likelihood of affecting the clinical outcomes; the probability is low 
(<50%) that the clinical experience with the intervention observed in the study will be 
attained in the US primary care setting. 
 
Key questions for appraising quality of qualitative research studies
34
: 
 Was an appropriate sample used for the research question? 
 Was the data collected appropriately? 
 Was the data analyzed appropriately? 
 Are the results of this study relevant to my own setting? 
 Are potential ethical issues addressed? 
 Is it clear what the researchers did in the study? 
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Appendix D. Table a. Strength of evidence rating from USPSTF Procedure Manual 
35
 
Level of 
Certainty 
Description 
High The available evidence usually includes consistent results from well-designed, 
well-conducted studies in representative primary care populations. These studies 
assess the effects of the preventive service on health outcomes. This conclusion 
is therefore unlikely to be strongly affected by the results of future studies. 
Moderate The available evidence is sufficient to determine the effects of the preventive 
service on health outcomes, but confidence in the estimate is constrained by 
factors such as: 
 The number, size, or quality of individual studies. 
 Inconsistency of findings across individual studies. 
 Limited generalizability of findings to routine primary care practice. 
 Lack of coherence in the chain of evidence. 
As more information becomes available, the magnitude or direction of the 
observed effect could change, and this change may be large enough to alter the 
conclusion. 
Low The available evidence is insufficient to assess effects on health outcomes. 
Evidence is insufficient because of: 
 The limited number or size of studies. 
 Important flaws in study design or methods. 
 Inconsistency of findings across individual studies 
 Gaps in the chain of evidence; 
 Findings not generalizable to routine primary care practice 
 A lack of information on important health outcomes. 
More information may allow an estimation of effects on health outcomes. 
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Appendix E. Table A: Category 1 Studies 
Author, Year Design, N Setting, Population 
Characteristics 
Comparisons, 
Measurement 
Intervals 
Results, Instruments Internal 
Validity 
External 
Validity 
Paris et al, 
2010
10
 
Prospective 
Cohort, 832 
Consecutive sample from 
French Asbestos Post-
Exposure Survey, 2005. 
Female: 7.7%, Age: 62, 
Current Smoker: 9.1%, 
Former Smoker: 45.1%, 
Asbestos Exposure- 
Light: 11.3%, Moderate: 
40%, Heavy: 26%,  
Unknown: 22.7%  
By exposure 
categories vs. 
control 
(unknown 
exposure). 
Baseline and 6 
months after 
screen. 
- Increased abnormal PCQ scores at T2 vs. 
T1 (32.6% vs. 20.5%). Increased among all 
groups (even normal screen) at T2 
compared to baseline. 
- Greater increase with abnormal screen 
results. 
- Patients with pleural plaques had higher 
scores at T2 than other groups at T2 
- 19% of those with normal T1 score had 
abnormal T2 Score 
Fair Poor 
Vierikko et al, 
2009
21
 
Prospective 
Cohort, 457 
Finnish workers with 
asbestos exposure. Group 
1 had prior asbestos 
screening, asymptomatic 
with no disease. Group 2 
and 3 from clinic patients 
with pulmonary disease. 
Age 64.7, Married: 
83.8%, Pack years: 17.1, 
Current Smoker: 17.9%, 
Former Smoker: 59.5%, 
Asbestos years: 19.2, 
Dyspnea: 40.1% 
By screen result 
(negative vs. 
false positive). 
Baseline and 1 
year after 
screen. 
- Health anxiety questionnaire scores lower 
after screening in both negative and false 
positive groups 
- Health anxiety scores higher in the FP 
group vs. negative group. 
- Perceived cancer risk (33.6%) higher than 
in other studies. 
   
Poor Poor 
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Appendix E. Table B: Category 2 Studies 
Author, Year Design, N Setting, Population 
Characteristics 
Comparisons, 
Measurement 
Intervals 
Results, Instruments Internal 
Validity 
External 
Validity 
Mazzone et al, 
2013
22
 
Prospective 
cohort, 1424 
Cleveland Clinic 
Screening Study.   
Age: 60.1, Female: 
54.3%, Current smoker: 
51%,  
One cohort. 
Baseline 
questionnaire, 
and every 6 
months for 2 
years. 
- 25 (out of 711 in screen group) Patients 
notified of nodules. EQ-5D lower after 
notification, no other metrics changed. 14 
/25 were NLST eligible. 
- Patients notified of nodule had higher 
imaging use at 6-months (25.5% vs. 9.3%), 
no diff in other health care use.  
Fair Poor 
Slatore et al, 
2013
23
 
Qualitative, 
Cross-
Sectional, 
19 
Veteran's Affairs. 
Asymptomatic with 
pulmonary nodule, under 
surveillance. Age: 66, 
Female: 5%, White: 
94%, Current Smoker: 
21%, High school or less: 
39% 
No comparison. 
Single 
interview. 
- Patients rarely understood follow up plans. 
- Most perceived nodule to be dangerous, 
level of care inadequate for their perceived 
severity. 
 - Variable degrees of distress response  
- Most patients know nodule is related to 
cancer and experience at least mild distress 
with diagnosis. 
Good Poor 
Wiener et al, 
2012
24
 
Qualitative, 
Cross-
Sectional, 
22 
Patients with pulmonary 
nodule from an urban-
underserved or rural 
referral center.  
Age: 60.7, Female: 86%, 
White: 77%, Current or 
Former Smoker: 68%, 
Mode of Discovery: 
symptomatic workup: 
18%, Incidental finding: 
82%, lung cancer 
screening: 0% 
No comparison. 
Single 
interview. 
- Almost all initially assume nodules are 
cancer.  
- Some patients experience confusion and 
stress that lasts for months when not 
adequately informed about the cancer risk of 
the nodule. 
- Anxiety and frustration over concerns not 
being fully addressed and the lack of 
attention given to the nodule, sometimes 
leading to poor adherence to further 
evaluation 
- It is helpful when clinicians use lay 
terminology, show CT images, and quantify 
cancer risk. 
Good Fair 
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Appendix E. Table C: Category 3 Studies 
Author, 
Year 
Design, N Setting, Population 
Characteristics 
Comparisons, 
Measurement 
Intervals 
Results, Instruments Internal 
Validity 
External 
Validity 
Park et al, 
2013
36
 
Prospective 
cohort, 430 
Consecutively enrolled 
NLST participants from 8 
sites, Dec 2003 to Mar 
2004. 
 Age, 61.0, Female: 
44.4%, White: 91.9%, 
Current smokers: 49.3%, 
Post-highschool: ~61%, 
Pack-years: 55 
One cohort. Before 
initial screen and 
before 1 year 
follow up. 
- Risk perceptions and cognitive and 
emotional determinants of behavior change 
(custom questionnaire) did not change 
significantly over time, or by screening 
result.  
- Changes in risk perceptions not associated 
with changes in smoking status at 1-year 
follow up.  
- Current vs. former smokers had higher 
risk perceptions for lung cancer and other 
smoking-related diseases. 
Fair Fair 
Aggestrup et 
al, 2012
26
 
Randomized 
Control 
Trial, 3701 
DCLST participants.  
Age: 57, Female: 44%, 
Current smoker: 76%, 
Pack-years: 36 
Screen vs. control 
arm. Before screen 
and after screening 
round. 
- At follow up both groups had increased 
anxiety, dejection, self-blame and behavior 
scores(COS), no difference in mean 
increase between groups.  
 
Fair Fair 
van den 
Bergh et al, 
2010
27
 
Randomized 
Control 
Trial, 630 
NELSON Trial, 
Consecutive enrollees 
from two centers. Female: 
53%, Age: 57.8, >High 
School Education: 27.7%, 
Current Smoker: 54.6, 
Pack-years: 40.1.  
Screen result Pre-
randomization, just 
prior to screen, 1 
week after screen, 
2 months after 
screen. 
- EQ-5D, STAI-6, & IES worse at T1 vs. 
T0 for both groups (statistically) 
- No clinically relevant changes over time 
- Distress and anxiety better at T2 vs. T1 
overall 
- No change in EuroQol-5 and STAI-6 
between T0, T1, T2 for whole sample 
- For indeterminate result, EQ-5D and 
distress worse at T3 vs. T2 (only clinically 
relevant change) and vs. T0.  
 
 
Fair Fair 
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Appendix E. Table C: Category 3 Studies continued. 
Author, 
Year 
Design, N Setting, Population 
Characteristics 
Comparisons, 
Measurement 
Intervals 
Results, Instruments Internal 
Validity 
External 
Validity 
Bunge et 
al, 2008
29
 
Prospective 
Cohort, 288 
NELSON trial.  Age: 60.3, 
Female: 48.1%, Current 
smoker: 74.7% 
By cancer risk 
perception (high vs. 
low). Day 1 before 
screen and 6 months 
after. 
- Those with high risk perception at baseline (14.6%) 
had higher median distress and mental component of 
SF-12.  
- All groups had lower IES at 6mo 
- At 6 months fewer perceived risk as high (10.5%) 
Good Fair 
Byrne et 
al, 2008
37
 
Prospective 
Cohort, 393 
Pittsburgh Lung Screening 
Trial.   Age: 60.2, Female: 
49.3% White: 94.5%, 
Years smoked: 40.8, 
Current Smoker: 59%, 
College Grad: 32% 
By screen results: 
negative, probably 
benign, or suspicious. 
Prior to screen, after 
results, 6 months after, 
12 months after. 
- State anxiety (STAI-6) and fear of cancer score 
increased after non-negative results. These decreased 
by 12 months after screening.  
- Negative screening results had stable fear of cancer 
and STAI-6 over time. 
- Lower anxiety among higher education and married. 
- Higher anxiety among smokers. 
- Baseline cancer risk perceptions are high (18%) and 
remain higher than reality after screening, regardless of 
result. 
- Risk Perceptions fall to 13% with negative screen, no 
change with non-negative screen (actual risk is <1%) 
     
Good Fair 
van den 
Bergh et 
al, 2008
28
 
Prospective 
Cohort, 336 
NELSON Trial. 
Consecutive enrollees 
from two centers. Female: 
49.1%, Age: 60.3, High 
school or greater: 19.4%, 
Current smoker: 74.7% 
One cohort. Sub-
grouped by 
demographics. 1 week 
before, one day after, 
6 months after 
baseline screen. 
- SF-12, EQ-5D, STAI-6, IES similar to population 
norm at baseline, no clinically significant difference 
over time.  
- Discomfort: 46.4% have discomfort awaiting results, 
50.5% dread results.  
 
Fair Poor 
Ford et al, 
2003
31
 
Retro-
spective 
cohort, 
4705 
PLCO participants from 
Detroit site. FP: 1137, 
Neg: 3568, True Pos 
excluded. 
Age: 62.3, Female: 55%, 
White: 84.2%, Post-High 
school: 69.3%, Current 
smoker: 14.4%, Former 
smoker: 48.7% 
By screen result 
(negative vs. false 
positive). Baseline 
screen and yearly 
follow up. 
- >50% increase in non-adherence among FP vs. Neg 
- Increased non-adherence among African Americans 
(OR: 1.5), women vs. men (OR: 1.4), current smokers 
vs. never smokers (OR=1.4), older,  lower education 
- FP cases were older, more male, more current 
smokers 
 
Good Fair 
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Patient Perceptions of Benefits, Harms, and Risks of Lung Cancer Screening 
Abstract 
Introduction: Patients eligible for participation in recently recommended lung cancer screening 
programs may be poorly informed about the benefits and harms of screening. We conducted a 
preliminary investigation of risk perceptions as well as perceptions of potential benefits and 
harms of lung cancer screening, among patients at increased risk for lung cancer. 
Methods: I performed a cross-sectional study of general medicine outpatients at increased risk 
of lung cancer (50-80 years old, at least 30 pack-year smoking history). I surveyed participants 
about the following topics: perceived effects of screening on smoking cessation, overall 
knowledge of lung cancer screening, perceptions of lung cancer risk, and reasons why people 
would want to get screened. I collected demographic and smoking history information necessary 
to use a lung cancer risk calculator, in order to compare calculated risk estimates with study 
participants’ perceived risk. 
Results: 24 eligible respondents were recruited. The knowledge accuracy on the 5 NLST-based 
questions was 17%. Average risk perception of getting cancer, and dying from cancer with and 
without screening over the next six years was 26%, 17.5%, and 25.1%, respectively. The most 
common reason cited to participate in screening was early detection allowing early treatment, 
and the most common reason not to get screened was fear or anxiety of the results, followed by 
financial concerns.  
Conclusion: Patients eligible for lung cancer screening overestimate their risk of getting, and 
dying from lung cancer. People at increased risk of lung cancer underestimate the potential 
harms and overestimate potential benefits of screening. 
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Introduction 
 Each year an estimated 158,000 premature deaths in the U.S. are attributed to lung 
cancer.
38
 Overall, smoking is responsible for around 440,000 premature deaths, 5 million 
potential life years lost, and estimated productivity losses valued around $96.8 billion each 
year.
39
 Smoking is a major cause of morbidity as well; the CDC estimated in the year 2000, 8.6 
million people suffered from 12.7 million smoking related diseases in the U.S.
40
  
 Due to the high disease burden and aggressive nature of lung cancer, there has been 
considerable effort to detect and treat cancer at earlier stages through screening programs. The 
largest and perhaps most significant study of lung cancer screening, the NLST, included over 
50,000 people at increased risk of lung cancer (55-74 year-olds, with at least 30 pack years, and 
if a former smoker, had not quit more than 15 years ago).
7
 The trial showed a 20% relative 
decrease in lung cancer mortality in those screened with LDCT vs. chest x-rays.
7
 These results 
were important considerations in the recent Grade B recommendation from the USPSTF for 
LDCT in screening patients at increased risk for lung cancer. This recommendation was for 
people that meet the same NLST eligibility criteria, but expanded the age range to 55-80 year 
olds.
8
 Several other groups have published similar guidelines for lung cancer screening eligibility 
(Appendix 1). 
 There are many potential benefits of LDCT screening beyond a 20% relative lung cancer 
mortality reduction.
7
 There may also be benefits in exposing individuals to the health care 
system, one of the most significant may be in increasing smoking cessation rates. 
41-43
 
Additionally, patients may be reassured by the screening process relieving anxiety about the 
possibility of having cancer.
21,27
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 Though the USPSTF’s review shows a net benefit in decreased lung cancer mortality, 
there are also substantial harms. In the NLST, 96.4% of positive screens were false positives 
resulting in many follow up diagnostic tests, additional radiation exposure, and invasive biopsies, 
bronchoscopies, and thoracotomies for individuals who did not have lung cancer.
7
 There is 
increased radiation exposure, time lost to screening, opportunity costs of health care resources 
spent, and overdiagnosis.
44
 Additionally, participants with abnormal screens experience adverse 
psychosocial effects and simply being invited to participate in cancer screening may also have 
negative psychological consequences for patients, as demonstrated in the preceding review.
22-
24,27-30,45
  
 Though the relative risk reductions are assuring, using the NLST mortality data, we 
calculate an absolute risk reduction of around 0.5% for the study sample as a whole and that 320 
people would need to be screened to prolong one life. The absolute risk reduction is highly 
variable, but can be estimated on an individual basis using a calculator from the Memorial Sloan 
Kettering Cancer Center based on smoking history, age, gender, and asbestos exposure.
46
 Using 
various risk factors, one study divided the NLST group into quintiles to show that further 
stratification of risk for redefining eligibility for screening could increase the precision; 
Kovalchik showed that screening the 60% of the sample at highest risk would have prevented 
88% of all the lung cancer deaths prevented in the NLST.
47
 
   In general, patients in lung cancer screening programs tend to overestimate their risk of 
lung cancer and, regardless of results of screening, surveys from before and after screening show 
long term perceptions of lung cancer risk remain elevated.
25
 Few past studies have investigated 
patient perceptions regarding their personal risk for lung cancer and their perceived benefit from 
screening with CT. Furthermore, patients' understanding of the various benefits and harms they 
 38 
 
may experience from screening may be influenced by anxiety surrounding lung cancer and their 
long term smoking exposure.
9
 This is important particularly in relation to patients’ potential 
benefits based on their underlying risk for developing clinically meaningful lung cancer. 
 This study sought to investigate whether patients understood the potential benefits and 
harms of LDCT screening. We also questioned whether patients would overestimate their 
personal cancer risk and misinterpret the risks involved in LDCT screening. We proposed to 
determine if our participants would neglect psychological harms and overall effect on quality of 
life of participating in lung cancer screening and wondered if there may be an association 
between education level and inaccurate risk, benefit, and harm perceptions. The original research 
presented in this paper was designed to determine to what extent these misconceptions exist by 
assessing patient conceptions of screening and comparing them with estimates of benefits and 
harms derived from the NLST data. The responses will be important in highlighting 
misunderstandings about screening and cancer risk. This pilot data will also be useful in 
designing future surveys and panel sessions that will be necessary to construct tailored decision 
aids and counseling services for patients eligible for lung cancer screening. 
  
Methods 
 Study Design. The study design was a cross-sectional interview questionnaire given by 
the author to patients that were eligible (or near-eligible) for lung cancer screening based on 
USPSTF recommendations (Appendix 1).  
 Subjects. I recruited patients ages 50-80 with 30 pack-year smoking history from a 
general-medicine outpatient clinic in a university hospital setting. I reviewed clinic appointment 
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schedules for potentially eligible participants based on age and smoking status; the electronic 
health record used would indicate only if the patient was a current or former smoker. I spent 2-3 
out of 5 weekdays recruiting subjects; these days were variable and based on my availability (a 
convenience sample), and potential participants volunteered for the study in order of attendance 
to clinic and depending on providers’ availability, preference, and schedule. Participants were 
offered no compensation, beyond general information about lung cancer screening. Participants 
were not required to be clinic patients; I also invited accompanying family or friends that met 
eligibility criteria. 
 Measurements. We developed a survey to measure desired study outcomes (Appendix 
2). Questions were designed to determine participant eligibility based on age, smoking history, 
and other risk factors (items 1-8, 17, 18, 28). The participant was asked about their clinic history 
and if they had ever been counselled by a physician about lung cancer screening; if they had ever 
had a CT scan, or had ever been screened for lung cancer, there were additional questions to 
determine results of these tests (items 9-13). For current smokers, questionnaire items inquired 
about perceived effects of screening participation on smoking cessation (items 14-16). Five 
multiple choice questions were designed to assess the participants' perceptions of the potential 
benefit and harm of screening (items 19-23).  
 Specifically, participants were asked to estimate their risk of developing lung cancer, and 
their risk of dying from lung cancer, both with and without screening, over a six year period 
(items 24-26). These risk predictions were later compared to risk estimates using a calculator 
from the Memorial Sloan Kettering Cancer Center.
46
 This risk calculator used age, gender, 
smoking years and cigarettes per day, quit status, and asbestos exposure to estimate risk of being 
diagnosed with and dying from lung cancer over the next six years, with and without screening.
46
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To determine relative risk perceptions, one question asked the participant to rate their risk 
relative to others at risk for lung cancer (item 27).  
 Two open-ended questions about why people should and should not undergo screening 
concluded the interview (items 29, 30). These questions were placed at the end of the survey to 
determine whether patients would consider, without being prompted, screening associated harms 
such as false positives and follow up invasive testing. Once patients finished responding, I 
provided probes about possible reasons one would not want to be screened and recorded whether 
participants agreed with these reasons or had additional opinions. These included issues such as 
finances, anxiety about testing and cancer, and access to a health care provider. Demographic 
information was collected, including height, weight, gender, race, education, and health literacy 
level (items 31-35). 
 Prior to beginning the survey, participants were given basic information about the lung 
cancer screening process. I ensured that the participant understood the definition of screening as 
a preventive service for asymptomatic individuals with a smoking history, using CT scans to 
look at the lungs. Participants were asked about their familiarity with a CT scan, and this mode 
of imaging was explained briefly when necessary. At the conclusion of the interview the 
participant was debriefed about the answers to the knowledge-based questions using NLST 
outcomes data. The participant's risk perceptions were discussed based on Kovalchik's risk 
quintiles, and finally concerns about potential risks of screening were addressed.
47
 After the 
survey, I gave participants information about risk and provided basic counseling about lung 
cancer screening. 
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 Analysis. The responses to knowledge-based questions (items 19-23), were graded and 
accuracy for each item was scored. I calculated mean responses to absolute risk perception items 
(Items 24-26) and compared these to mean calculated risks. Individual responses to knowledge-
based and risk-perception items (items 19-27 in questionnaire), total number of correct 
knowledge based items, as well as comparative risk were assessed with chi-squared test for 
associations by education level. Due to limited sample size, self-reported education (item 26) 
was dichotomized into those with high school education or less, and those with any education 
beyond high school. Kruskal-Wallis tests were used for associations between absolute risk 
perceptions (items 24-26) and education. Data analyses were performed using Stata (Release 13; 
StataCorp LP, College Station, TX, USA). 
 
Results: 
 Participation. Of the 234 patients marked as smokers in the medical record, I 
approached 79 patients over ten clinic mornings. Overall, 16 declined, 38 were ineligible, 1 was 
unable to complete the survey, and 24 were interviewed for a participation rate of 30.3%. Of the 
234 clinic patients marked as smokers by the electronic medical record, 44.4% were current 
smokers. One interview was given via telephone to an interested patient who was missed in 
clinic and one interview was given to an eligible family member (non-patient) of an ineligible 
clinic patient. 
 Sample characteristics. The sample consisted of 24 respondents that met our eligibility 
criteria. The majority of respondents (19/24) met USPSTF screening guideline eligibility; two 
were young (51 and 54), but will be eligible once they turn 55, and three had quit over 15 years 
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ago (16, 22, and 33 years).The sample is summarized as follows: female: 50%, average age: 64.6 
years, current smoker: 33%, pack-years: 43 ± 15.1 years, white: 33%, COPD or emphysema: 
71%, asbestos exposure: 50%, education greater than high school 37% (Table 1). 
 Knowledge of benefit & harm. On the five multiple choice questions regarding NLST 
trial results, the respondents averaged 17% accuracy. The question with the most correct 
responses was item 13, which asked: about how many individuals would receive an abnormal 
screening result (42% correct)? The question with the most incorrect responses was item 14, 
which asked what the false positive rate would be in those receiving abnormal screen results (0% 
correct) (Table 2). 
 The multiple-choice, knowledge-based questions had interval valued answer choices and 
so their responses may be summarized as follows: 83% overestimated the number who would 
have their lives prolonged, 63% underestimated the number of invasive procedures that would 
not eventually find cancer, 50% underestimated the proportion whom would have an abnormal 
screen result, 100% underestimated the proportion of false positive screen results, and 88% 
overestimated the benefit in absolute mortality reduction. 
 Quantitative analysis of knowledge-based questions showed statistically significant (at 
5% alpha) association of higher educated respondents answering item 19 (how many screened 
would have their lives prolonged?) correctly more frequently than lower educated respondents 
(p=0.025). However, a Bonferroni adjustment for these tests run on each of the 5 knowledge 
based questions would change a necessary alpha to 0.01, making this association no longer 
statistically significant. No other individual items showed statistically significant variation in 
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accuracy by education level. The total number of correct knowledge-based questions did not vary 
by education level. 
 Risk Perception. When asked to estimate their personal risk of being diagnosed with 
lung cancer over the next six years, respondents averaged 26% probability (range from 0-80%). 
Respondents’ estimation of their risk of dying from lung cancer if they were in a screening 
program averaged 17.5% (range from 0-80%), and their estimated risk of dying from lung cancer 
without screening averaged 25.1% (range from 0-80%).  
 Of the 22 respondents who estimated their risk of dying from lung cancer over the next 
six years with and without screening, respectively, seven and six participants estimated a 0% 
chance. All other respondents over-estimated their risks of dying from lung cancer over the next 
six years compared with the results from the Memorial Sloan Kettering Calculator.
46
 Of the 15 
respondents who gave non-zero estimates of their risk of dying from lung cancer given 
participation in screening, the average response was 24.6%; the average estimate was 1.53% 
using the risk calculator. Of the 16 respondents who gave non-zero estimates of their risk of 
dying from lung cancer over the next six years without screening, the average response was 
34.5%; the average estimate was 2.03% using the risk calculator. This group overestimated their 
risk of dying from lung cancer by 23% and 32% points, and in relative terms, this group’s 
perceived risk was 16 and 17 times the risk given by the calculator estimate, with and without 
participation in screening, respectively. The predicted effects of LDCT screening on relative 
reductions in lung cancer mortality were 28.7% for participant responses and 24.6% for 
calculated estimates. 
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 When asked to compare their risk of getting lung cancer to the risk of other people at 
increased risk for lung cancer, 65% (15/23) believed their risk to be the same or less than others 
(Table 3).  Individuals estimated absolute and comparative risk perceptions did not vary by 
education level.  
 The free-response questions about why individuals would or would not want to get 
screened for lung cancer reached saturation over the course of multiple interview days. The most 
common theme for why individuals would want to get screened was early detection leading to 
early treatment and better outcomes; 16 of the 24 respondents spontaneously (without any probe 
or structured lead-in) generated this response. Five respondents brought up anxiety or curiosity 
about having cancer, and the desire to know the diagnosis as reasons to get screened. When 
asked why someone would not want to get screened, the majority mentioned anxiety or fear 
surrounding the test and receiving results (17 out of 24, 4 of these agreed after being probed if 
this could be a concern). Most respondents had little to say in response to this question, and so a 
standardized probe used to ask participants if they thought that individuals might have certain 
concerns (financial, anxiety, access, etc.) elicited additional responses. Of the 24 respondents, 12 
mentioned financial concerns (9 of these responses were after probe), and 9 respondents 
mentioned access or difficulty getting to the doctor or getting the tests (4 after probe). 
 Screening effect on smoking cessation. Eight current smokers participated in the study. 
These individuals all reported they would be just as likely or more likely to quit smoking if they 
participated in screening. Participants were also asked about their likelihood to quit if they 
received a normal, or an abnormal screening result. If they received normal results, all would 
also be just as likely or more likely to quit. If they received abnormal screening results, only one 
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respondent answered they would be less likely to quit, all others would be just as likely or more 
likely to quit smoking (Table 4). 
  
Discussion: 
 The goal of this study was to examine the risk perceptions of those eligible or near-
eligible for lung cancer screening by LDCT, and to assess their level of understanding regarding 
the potential benefits and harms of screening. This relatively small (n=24) convenience sample 
study suggests that this population may lack an understanding about the potential benefits and 
harms of screening, and may overestimate their potential risk for developing and dying from 
lung cancer. 
 On knowledge-based questions, respondents performed particularly poorly when asked to 
estimate how many of those receiving abnormal screen results would not have cancer (false 
positives); none of the 24 respondents answered this question correctly suggesting that 
participants overestimate the accuracy of LDCT screening. The question answered correctly 
most often regarded the percentage of those screened who would have abnormal results (42% 
correct). I believe this item was answered correctly more often than others because it used wide 
ranges (particularly for the correct response), and the correct response was not one of the 
extreme choices (as it was in the other questions). Also, individuals overestimate their absolute 
risk of cancer, and so are likely to consider the possibility of getting abnormal screen results. 
Because most answer choices were presented in ordinal fashion, I concluded that respondents 
overestimate the diagnostic accuracy and mortality benefit of lung cancer screening with LDCT 
and underestimate the potential harms of screening. 
 46 
 
 Knowledge of screening & risk perception. Overall, our study sample performed 
poorly on knowledge based questions (17% accuracy overall). The participants in our study all 
underestimated the rate of false positives in LDCT screening. Other studies show that patients 
have high expectations for both sensitivity and specificity of the screening CT exams: 92% 
disagreed with the statement, ‘‘If a test says I do NOT have lung cancer when I DO, that is OK 
with me,” and 84% disagree with the statement, ‘‘If a test says I may have lung cancer when I do 
not that is OK with me.” 48 The rate of abnormal, and follow up false positive screen results is an 
important factor for those considering screening; the preceding review of psychological effects 
of screening has shown that many patients experience psychological distress in response to 
receiving indeterminate results, or undergoing surveillance for possibly pre-cancerous lesions. 
As Kovalchik has shown, stratifying NLST participants into risk quintiles may improve the 
balance of benefits and harms: 60% of NLST participants at highest risk for lung cancer 
mortality make up 88% of all lung cancer deaths prevented by screening.
47
 This evidence is 
promising in that we may be able to target screening in those who are at highest risk, and prevent 
possible harmful effects of screening in those who may benefit less. 
 The study sample overestimated their risk of being diagnosed with, and dying from, lung 
cancer. Results of other studies are concordant with the high absolute risk perceptions prevalent 
among the sample in this survey. Among participants in one CT-trial, 64% and 76% perceived 
high absolute and comparative lung cancer risk, respectively, and 94% reported concern over 
developing lung cancer.
48
 Our study sample differs from these results on comparative risk, 
however; in our sample risk compared to other smokers was rated as average, or as less than 
average.  
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 Through my experience interacting with patients in interviews, those eligible for 
screening know little about LDCT and lung cancer screening in general, but appear highly 
interested in the concept as a means of early detection and improved treatment outcomes. Other 
literature has shown that though awareness of CT screening may be low even in people who are 
close to lung cancer patients (77% unaware of CT screening), there is high interest upon being 
informed of screening: 67% were at least somewhat interested in being screened and 62% 
indicated they would likely enroll in a lung cancer screening program if it were free.
49
 There are 
many factors influencing participation in lung cancer screening, and these may have significant 
implications for the broad implementation of screening and properly informing those eligible 
about the screening process. In a survey of Dutch patients given information and a questionnaire 
about lung cancer and CT screening prior to participation in the NELSON trial, there were 
important differences in the lung cancer knowledge and risk perceptions between participants 
who enrolled in the trial and those who opted out. Overall, knowledge about screening was low 
in both groups (around one-third responded "do not know" and about 40% underestimated the 
rate of indeterminate, or abnormal/positive findings).
50
 Screening participants vs. non-
participants answered questions about lung cancer screening more accurately (51.4% vs. 38.1%) 
and had more knowledge about the trial and lung cancer overall (72.7% vs. 53.6%).
50
 More 
screening participants showed a positive attitude toward screening than non-participants (98.7% 
vs. 63.8%) and participants more often reported high lung cancer risk perceptions (14.4% vs. 
6.5%).
50
 This is important in considering generalizability of the lung cancer screening trial 
results to a population which may have a much less informed position about the screening 
process than those participating in the trials. In general, all patients are not likely to understand 
the procedural details and risks involved in lung cancer screening.  
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 To screen, or not to screen? The conversational portion of the interview elicited few 
unique responses and very limited interactive dialogue, suggesting that patients who are eligible 
for lung cancer screening have not seriously considered the details of the screening process. Only 
one participant acknowledged having actively researched lung cancer screening with LDCT; this 
patient was well-educated, answered knowledge-based questions more accurately (closer on an 
ordinal scale), and had reasonable personal risk perceptions. It may be that as patients are 
exposed to the limitations involved in the screening process they may be more skeptical and 
more prone to consider their personal situation, rather than deferring to guidelines and 
automatically participating. 
 The most common reasons to participate among those considering the NELSON trial was 
an advantage in detecting lung cancer earlier (80%) while the most common reason not to 
participate was the amount of effort involved (~50%).
50
 These responses rates were similar in 
this study; 67% mentioned benefits of early detection, and 38% mentioned difficulty with access 
or getting to the tests. A more common concern in my study sample was fear and anxiety (71%) 
and financial costs of screening tests (50%), though the NELSON trial took place in a 
nationalized health system, likely making financial costs a less significant concern 
 Cessation. In our small sample of current smokers, hypothetical participation in a 
screening program did not seem to have a negative effect on respondents’ intentions to quit 
smoking, and 50% of respondents reported that screening would make them more likely to quit. 
 There is mixed evidence in the literature regarding screening's effect on smoking 
cessation. Overall, quit rates among the general population of U.S. smokers are lower in older vs. 
younger smokers; of those 50-64 years old, annual quit rates are around 65% for any serious 
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attempt, 35% for at least one day, and 5% for at least 6 months of cessation.
51
 Several studies 
have reported smoking cessation rates as well as attitudes regarding cessation among lung cancer 
screening trial participants. In one study, 74% of screening participants report increased 
motivation to quit and 49% reported either having reduced or quit smoking after screening.
52
 In 
the Pittsburgh Lung Screening Study, 58.5% reported any quit attempt and 27.2% reported a quit 
interval greater than 30 days.
41
 Among a sample NLST participants, 31.5% had greater readiness 
to quit after the first screening round.
53
 However, in the Danish Lung Cancer Screening Trial 
there was no difference in quit rates  among current smokers and no difference in relapse rates 
for former smokers in screen vs. control arm one year post screen.
54
 Beyond participation in 
screening, the screen result may have some effect on cessation rates as well. Abnormal results 
can lead to increased cessation readiness and higher quit rates in current smokers and a lower 
relapse rate in former smokers, whereas negative results can lead to less readiness to stop 
smoking.
41,53,54
 Despite possible negative or positive psychological effects of screening on 
cessation, CT screening may represent a clinical opportunity to intervene and promote smoking 
cessation through creating a clinical relationship and providing the patient with therapeutic 
opportunities.
41,53
 Ideally though, smoking cessation counselling should be done in a primary 
care setting; it is unfortunate that an intervention as intense as LDCT screening could 
inadvertently be used as a method to motivate patients to stop smoking. 
 The potential to intervene and improve cessation rates may be a very important aspect of 
screening programs, as cessation will not only lower lung cancer risk, but improve health status 
in many other body systems as well. The dramatic effect of variable cessation rates is seen in a 
cost-effectiveness analysis of LDCT screening. Hypothetically, if screening could double 
participants’ background cessation rate from 3% to 6%, it would cost around $40,000/QALY 
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(women) to $73,000 (men); however, if screening halved the cessation rate to 1.5% it would cost 
$880,000/QALY (men) to >$1 million/QALY (women).
55
 
 Moving forward & making better choices. Traditional medical practice may be thought 
of as illness-oriented medicine, which involves searching for a distinct fault, diagnosing this fault 
as disease, and then systematically treating the disease to cure.
56
 LDCT screening practice seems 
to fall into this doctrine. Another mode of medical thinking is patient-centered medicine which 
involves making an overall diagnosis by capturing everything a physician knows about the 
patient and considering each patient as a unique human being.
56
 
 One aspect of patient-centered medicine is shared decision making, in which patients take 
an active role with clinicians in understanding their health care options. This process can 
facilitate patient autonomy, improve patient-clinician relationships, and improve patient 
knowledge in order to give a more realistic perspective about the screening process and what a 
patient might expect to experience.
57
 Ultimately, decisions should be based on the outcomes 
patients find most important; these are often not intermediate outcomes like blood pressure or 
cancer cell-type which may affect management but are not necessarily integral to the patient's 
experience.
58
 
 Though certain patients may be interested and may benefit from shared-decision making, 
certain medical concepts, such as the risk of harms in screening, may be difficult to comprehend. 
Patients with low literacy and numeracy have particular difficulty, but even well-educated 
patients experience confusion due to clinicians’ use of ambiguous terminology when discussing 
risk.
59
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  According to Sheridan, to properly engage patients in decision making a clinician can 
ensure the patient
59
:  
1. Understands the risk or seriousness of the disease or condition to be prevented. 
2. Understands the preventive service, including the risks, benefits, alternatives, and 
uncertainties 
3. Has weighed his or her values regarding potential benefits and harms associated with the 
service  
 The results of this study will be used to plan further investigation of patient perceptions 
of risk and the screening process. This information will be important to better engage patients 
through these three guidelines and improve understanding of their options for screening, and help 
tailor decisions to meet their needs. One important aspect we considered in creating our survey 
and in moving forward in this arena is properly conveying risk information to patients. Risk 
perception can be manipulated by the mode of presentation; patients view treatments more 
favorably when the benefits are explained with relative risk reduction rather than absolute risk 
reduction (often absolute risk is a smaller number), and rather than number needed to treat (a 
difficult concept for many patients to comprehend).
60
 In our survey, absolute risk reduction was 
chosen to make the presentation of risk more personalized to the individual patient and show the 
limits of screening for individuals (an absolute risk reduction of all-cause mortality around 
0.5%)
7
. Nearly all respondents (88%) overestimated the benefit of LDCT screening in terms of 
absolute risk reduction. This same NLST data was used by the USPSTF to determine that a 20% 
relative reduction in lung cancer mortality was a large enough effect to recommend LDCT 
screening (with moderate certainty).
8
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 I also considered effectiveness of various tools to help explain the NLST numbers during 
post-interview counseling. In this research I have also learned that choice of illustrative figures 
and tables can also affect conceptualization of information; for instance, vertical bar charts are 
significantly better at conveying numerical information than pie charts.
61
 With the new USPSTF 
recommendation, the number of patients seeking LDCT screening will likely increase along with 
the need to inform patients of their options. An ultimate goal would be to create decision support 
tools to assist individuals in making choices regarding screening participation. 
 Lung cancer screening is a very new topic and though the potential harms have been 
outlined in many reviews, there is still controversy regarding how these harms balance with 
benefits.
9
 As demonstrated in the preceding review, few good-quality studies have been 
successful and consistent in determining psychological harms associated with lung cancer 
screening. Additionally, information about patients’ understanding of the risks involved in 
screening is also limited.  
 I asked whether patients would place great faith in the screening process’ ability to 
improve their well-being. Would they overestimate or underestimate the potential benefits of 
LDCT screening? Would patients misperceive their personal cancer risk and the risks of LDCT 
screening? I also asked whether patients would neglect psychological harms and the overall 
effect on quality of life from participating in lung cancer screening. This study has answered 
these questions, in a limited sample size, to at least some degree.  
 The original research presented in this paper was designed to show these misconceptions 
by using data from the NLST, the trial holding the most weight in the USPSTF's recent decision 
on lung cancer screening.  
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 Strengths and limitations. One strength of this study was the use of a single interviewer 
to maintain homogeneity of the survey process and results recording. This was also useful in 
flexibility of the interview process to answer the needed questions in the survey while providing 
appropriate feedback to individual clinic patients about the screening process and their potential 
options. The presence of a multi-disciplinary team of researchers in consultation with the study 
and survey design was integral to developing a survey that would collect meaningful information 
for our target outcomes.  
 This study had many weaknesses. It consisted of a convenience sample of 24 participants, 
and so is limited in power and generalizability, and the findings have a moderate to high degree 
of uncertainty. The non-random nature of participant recruitment contributes to significant 
participation bias. The use of knowledge based questions with multiple choice responses is a 
weakness; in a prior online survey we provided the answer choice “I don’t know,” which was 
often the most selected option. This study forced participants to choose an option, though many 
stated during the interview that they did not know the answer. These responses included a wide 
range from “I’d guess [answer]” to “how could one possibly know that,” and one respondent 
who becoming visibly angry. Use of multiple choice questions likely introduces some random 
error in some individuals selecting the correct response. We used ordinal presentation of answer 
choices to better present information, but this may have led individuals that do not know the 
answers to select more moderate values, when the answers were often the more extreme choices.  
 One question (item 20) was particularly difficult to answer; I believe this question was 
poorly worded and created a hypothetical situation that was several steps down the screening and 
diagnosis process and was too complex for many to comprehend. The ordinal nature of the 
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answer choices may have been somewhat leading towards more moderate answer choices, but 
this presentation was chosen to improve comprehension and flow of the survey. 
 Asking individuals to estimate their own cancer risk was also very difficult and many 
respondents were frustrated or made anxious by having to come up with a probability that they 
would die from cancer in the next six years. Several responded with zero-percent chances, and it 
was difficult to tell if these responses were actual mental configurations of a probability, or 
emotional responses representing hope that they would not get cancer. 
 Our survey was developed by the primary research team; its items did not undergo 
cognitive testing, and there is significant potential for measurement bias. Some of the steps 
necessary for a high quality study with good internal validity were bypassed for this study given 
lack of funding; however, one of the goals of collecting primary data in this study was in grant 
writing for a future project. This was a pilot study whose data will also be useful in designing 
future surveys and panel sessions that will be necessary to construct tailored decision aids and 
counseling services for patients eligible for lung cancer screening. 
 
Conclusion: 
 Patients eligible for lung cancer screening overestimate their risk of getting, and dying 
from, lung cancer. They underestimate potential harms and overestimate potential benefits of 
LDCT screening. The results of this study are important in considering what patients at increased 
risk of lung cancer understand about the screening process and how they believe screening may 
benefit or harm them, while considering how they view their personal risk profile. I hope that the 
experience gained and the responses analyzed here will lead to further meaningful investigation 
that can help better inform those at increased risk of lung cancer about their options for 
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screening, so they may make the choice that best fits with their unique risk profile and situation 
in life.  
 Future research will be conducted by the research team involved in this study. Assuming 
LDCT is more widely implemented, given the USPSTF’s recommendation, there will be more 
opportunities to study the effectiveness of lung cancer screening and the psychological 
implications of LDCT screening for patients. The immediate objectives should be improving on 
the design of this study to generate better evidence on patient risk perceptions, and their 
understanding of the screening process. This will allow for development of educational and 
counselling tools to better inform patients that are considering screening programs. Future 
research should then focus on developing high quality prospective trials on how such informed-
decision making tools perform in allowing patients to make the best decisions for their particular 
value sets. Scientists should also investigate the long term psychological effects of screening to 
improve understanding of this category of harms. Finally, due to the increasingly cost-conscious 
focus of medical and public health systems, wide-scale implementation of LDCT screening 
should attempt to capture as much information as possible to allow good-quality cost 
effectiveness analyses of this service at a societal level to demonstrate efficient resource 
utilization. 
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Tables and Figures 
 
Appendix 1. Lung cancer screening guidelines. Adapted from UpToDate.
62
 
Organization Recommendation Year 
US Preventive Services 
Task Force 
Recommends annual low-dose CT scan screening for 
high-risk individuals (ages 55 to 80 years with a 30 
pack-year history of smoking and current smoker or quit 
within past 15 years). Discontinue when person has not 
smoked for 15 years or if limited life expectancy.
8
 
2013 
American Cancer 
Society  
Recommends annual low-dose CT scan screening for 
high-risk individuals (age 55 to 74 years with 30 pack-
year history of smoking and current smoker or quit 
within past 15 years). Informed individual decision 
making before testing.
63
 
2013  
American Association 
of Thoracic Surgery 
(AATS) 
Recommends annual low-dose CT scan screening for 
high-risk individuals (age 55 to 74 years with 30 pack-
year history of smoking and current smoker or quit 
within past 15 years) or age 50 with cummulative risk >5 
percent over next five years.
64
 
2012 
National 
Comprehensive Cancer 
Network 
Recommends annual low-dose CT scan screening for 
high-risk individuals (age 55 to 74 years with 30 pack-
year history of smoking or 20 pack-year history with an 
additional risk factor).
65
 
2011 
Canadian Task Force 
on the Periodic Health 
Examination 
Recommends against the use of chest x-ray in 
asymptomatic persons. Evidence is insufficient to 
recommend for or against screening with spiral CT in 
asymptomatic persons.
66
 
2003 (under 
review in 
2014) 
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Table 1. Sample Characteristics (n=24 unless otherwise noted) 
Characteristic % or mean 
(std dev) 
Min-
Max 
Age 64.63 
(6.82) 
51-78 
Female 50%  
Current Smoker 33%  
Smoking Years 38.8 (10.2) 15-60 
Years Since Quit 
(n=16) 
10.4 (8.7) 1-33 
Packs Per Day 1.2 (0.48) 0.33-2.5 
Pack-Years 43 (15.1) 15.8-75 
White 33%  
Black 67%  
COPD or Emphysema 71%  
Asbestos Exposure 50%  
Positive Family 
History of Lung 
Cancer (n=23) 
35%  
Counseled about 
screening 
17%  
Prior CT Scan 75%  
CT for Screening 4%  
Education: High 
School or less 
63%  
Health Literacy: needs 
help reading at least 
sometimes 
29%  
 
  
 58 
 
Table 2. Correct responses per question 
Item number and question asked. % Correct 
19. Out of 1000 people who get screened for lung cancer, about how 
many will have their lives prolonged? 
 
17 
20. Out 1000 people who are screened, about how many will end up 
getting an invasive procedure, such as a lung biopsy, that doesn’t find 
cancer? 
 
13 
21. What percentage of people who get screened for lung cancer will 
have an abnormal, or “positive,” result? 
 
42 
22. What percentage of people who have an abnormal, or “positive”, 
result from lung cancer screening DO NOT end up having cancer? 
 
0 
23. The chance that getting a CT scan for lung cancer screening will 
reduce my risk of dying of lung cancer over the next 6 years is. 
 
13 
 
Table 3. Absolute and Comparative Risk Perceptions, (n=23). Estimated risk from Memorial 
Sloan Kettering Lung Cancer Risk Calculator
46
 
 mean  % (std dev) Min-Max Estimated 
Risk % 
My Risk of getting lung cancer in 
the next 6 years 
26 (30.6) 0-80 n/a 
My Risk of dying from lung cancer 
in the next 6 years with screening 
17.5 (22.5) 0-80 1.7 
My Risk of dying from lung cancer 
in the next 6 years without 
screening 
25.1 (29.5) 0-80 2.1 
    
Compared to others at risk for lung 
cancer, my risk of dying from lung 
cancer over next 6 years is: 
Number %  
Much less than others 3 13  
Less than others 7 30  
Same 5 22  
More than others 8 35  
Much more than others 0 0  
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Table 4. Screening effect on cessation, (n=8) 
 Much less 
likely 
Less likely Same More likely Much more 
likely 
Likelihood to quit if in 
Screening Program 
  4 3 1 
Likelihood to quit if 
normal screen result 
  6 2  
Likelihood to quit if in 
abnormal screen result 
 1 3 3 1 
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Appendix 2. Survey handout. (Correct responses to knowledge based questions marked) 
 
Lung Cancer Screening: Patient Perceptions of Risks vs. Benefits 
Study Information 
 You have been asked to complete this anonymous survey as part of a research project conducted 
by Josh Wallace, a graduate student at the University of North Carolina, as part of his degree 
requirements. This purpose of the research project is to help us understand what patients know about lung 
cancer screening.  
 The survey, which will ask you questions about lung cancer screening, should take less than 20 
minutes of your time and is voluntary. You may stop taking the survey at anytime, and you may skip any 
question for any reason.  You will not receive any direct benefit from being in this research study. The 
only possible risk to you of participating in this research study might be embarrassment if your answers 
became public, but that is very unlikely.  All possible measures have been taken to protect the 
confidentiality of your answers.  
 We will report only summaries of the aggregated data.  This means that your responses will be 
combined with all of the other responses received and will not be able to be identified as yours. Deductive 
disclosure, which is the discerning of an individual respondent's identity and responses through the use of 
known characteristics of that individual, is possible but unlikely. 
 If you have any questions about this research before or after you complete the survey, please 
contact Josh Wallace at joshua_wallace@med.unc.edu. If you have any concerns or questions about your 
rights as a participant in this research, please contact the UNC Institutional Review Board at 919-966-
3113 or irb_subjects@unc.edu.  
 By completing this survey, you agree to be a participant in this research. 
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Lung Cancer Screening Eligibility Assessment Instrument 
 
1. What is your age? _______ 
 
2. Have you ever been a smoker? 
☐ Yes 
☐ No 
☐ Don’t Know/Not Sure 
 
3. Do you smoke cigarettes now? 
☐ Yes 
☐ No  
 
For FORMER SMOKERS 
4. For about how many years were you a smoker? ___ 
 
5. About how many cigarettes on average did you smoke per day? There are 20 cigarettes in a 
normal pack. _____ 
 
6. How long ago did you quit smoking? ______ 
 
FOR CURRENT SMOKERS 
7. For about how many years have you been a smoker? ____ 
 
8. About how many cigarettes on average do you smoke per day?  There are 20 cigarettes in a 
normal pack. _____ 
 
Pack years = Packs per day * years as smoker 
 
Eligibility Requirements 
Age = 50-80 
Pack years 30 or more 
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Survey 
Several organizations, such as the American Cancer Society, are now recommending screening for lung 
cancer using a low dose CT scan for certain people.  We are trying to understand what you may know 
about the new lung cancer screening test.  It’s okay if you do not know the answers. 
Risk Status/Eligibility 
9. Is this your first visit to this clinic? 
☐ Yes 
☐ No 
10. What is the purpose of your visit? 
11. Before you came to the clinic: had you ever been counseled about, or had a health care provider ever 
explained the risks of screening for lung cancer? (Yes/No) 
☐ Yes 
☐ No 
12. Have you had a CT scan of your chest before? 
☐ Yes (Answer 4a) 
☐ No (Answer 4e) 
12a. Why was this scan performed (if lung cancer screening, answer 4b-d)? 
12b. How many times have you had a CT scan for lung cancer screening? 
12c. When was the last time you had a CT scan for lung cancer screening? 
12d. What were the results of your CT scan for lung cancer screening? 
12e. Has your doctor recommended that you get a CT scan for lung cancer screening? 
13. Do you remember the name of the doctor or clinic that referred you here?  
☐ Yes [WHO?___________________]  ☐ No 
For CURRENT SMOKERS: 
14. Would you be more or less likely to quit smoking if you participate in a lung cancer screening 
program?  
☐ Much less likely to quit 
☐ Less likely to quit 
☐ About the same 
☐ More likely to quit 
☐ Much more likely to quit 
15. How would a normal result from lung cancer screening affect your chances to quit smoking? 
☐ Much less likely to quit 
☐ Less likely to quit 
☐ About the same 
☐ More likely to quit 
☐ Much more likely to quit 
16. How would an abnormal result from lung cancer screening affect your chances to quit smoking? 
☐ Much less likely to quit 
☐ Less likely to quit 
☐ About the same 
☐ More likely to quit 
☐ Much more likely to quit 
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For ALL: 
17. Do you have emphysema or COPD? 
☐ Yes 
☐ No 
18. Have you been exposed to asbestos at work? 
☐ Yes 
☐ No 
We’re going to ask you some questions about what you may or may not know about lung cancer 
screening for people who meet the screening recommendations. 
19. Out of 1000 people who get screened for lung cancer, about how many will have their lives 
prolonged? 
☐ About 5 (correct) 
☐ About 20 
☐ About 100  
☐ 200 or more 
20. Out 1000 people who are screened, about how many will end up getting an invasive procedure, such 
as a lung biopsy, that doesn’t find cancer? 
☐ 0-10 
☐ 10-20 
☐ 20-30 
☐ 30-40 (correct) 
☐ More than 40  
21. What percentage of people who get screened for lung cancer will have an abnormal, or “positive,” 
result? 
☐ Less than 10% 
☐ 10-20% 
☐ 25-40% (correct) 
☐ More than 50% 
22.  What percentage of people who have an abnormal, or “positive”, result from lung cancer screening 
DO NOT end up having cancer? 
☐ About 5% 
☐ About 25% 
☐ About 50% 
☐ About 75% 
☐ About 95% (correct) 
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Now we want to know about lung cancer screening and risk of lung cancer for you personally. 
23. The chance that getting a CT scan for lung cancer screening will reduce my risk of dying of lung 
cancer over the next 6 years is. 
☐ Less than 1% (correct) 
☐ About 5% 
☐ About 10% 
☐ About 20% 
☐ About 30% 
 
24. My risk for getting lung cancer in the next six years is _____  
25. My risk for dying from lung cancer in the next six years WITH screening is  _____. 
26. My risk for dying from lung cancer in the next six years WITHOUT screening is _____. 
27. Compared to other people at risk for lung cancer, my personal risk: 
☐ Much lower than average 
☐ Lower than average 
☐ About the same as average 
☐ Higher than average 
☐ Much higher than average  
WHY DO YOU THINK SO? 
 
28. How many people in your family have had lung cancer?  
 
Next we’re going to ask you some questions about lung cancer screening and risk of lung cancer in 
general.  
29. In your opinion, why might people want get screened for lung cancer?  
30. Why might people not want to get screened for lung cancer? Probe: physical, psychological, financial 
strain, and opportunity costs. 
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Now I’d like to ask you some questions about yourself. 
31. Are you a: 
☐ Man 
☐ Woman 
32. What is your current: 
 Height:  
 Weight: 
33. What race or ethnicity do you consider yourself to be?  Choose the one that applies to you most. 
☐ Latino or Hispanic 
☐ American Indian or Alaskan Native 
☐ Asian 
☐ Black or African-American 
☐ Native Hawaiian or Pacific Islander 
☐ White 
☐ Other _________ 
34. What is the highest grade you have completed? 
☐ 7th grade or lower 
☐ 8th-11th grade 
☐ High school graduate or GED 
☐ Some college or vocational school 
☐ 2 year college degree 
☐ 4 year college degree 
☐ Professional or graduate degree 
35. How often do you need to have someone help you when you read instructions, pamphlets, or other 
written materials from your doctor or pharmacy? 
☐ Never 
☐ Rarely 
☐ Sometimes 
☐ Often 
☐ Always          
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